我國藥品質(zhì)量公告制度具有充分上位法依據(jù)和嚴厲的制裁性，在實踐中應充分保障被公告單位的知情權(quán)和復驗權(quán)、申訴權(quán)以及公眾對藥品質(zhì)量的知情權(quán)。為此，藥品質(zhì)量公告應重點關(guān)注不合格報告書的簽收、藥品生產(chǎn)企業(yè)的確認、被公告單位的復驗和申訴以及公告的及時性和完整性。為更好發(fā)揮藥品質(zhì)量公告的作用，建議有關(guān)部門在重點落實上述要點的基礎(chǔ)上進一步建立并執(zhí)行標準操作規(guī)程，杜絕僥幸心理，重視上游管理、輿情監(jiān)測和大數(shù)據(jù)利用。

Drug quality disclosure had sufficient upper-level legal basis and strict sanctions, and should fully protect the rights to know, re-test and appeals of the disclosed units, as well as the public's right to know the quality of drugs. To this end, the drug quality disclosure should focus on the signing of the report of substandard drugs, the confirmation of the drug manufacturer, the retest and appeal of the disclosed units, and the its timeliness and completeness. In order to better play the role of the drug quality disclosure, it is suggested that the relevant departments further establish and implement SOPs, reject fluke psychology, and attach importance to upstream management, public opinion monitoring and the use of big data on the basis of focusing on the implementation of the above key points.

R951